Peripheral F2‐isoprostanes and F4‐neuroprostanes are not increased in Alzheimer's disease
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Quantitative biomarkers of oxidative damage, such as the F 2‐isoprostanes (IsoPs) and F 4‐neuroprostanes (F 4‐NeuroPs), may be useful in assessing progression and response to therapeutics in patients with Alzheimer's disease. F 2‐IsoPs and F 4‐NeuroPs are reproducibly increased in brain and cerebrospinal fluid of Alzheimer's disease patients; however, results in blood and urine have been conflicting. We tested the hypothesis that F 2‐IsoPs and F 4‐NeuroPs in plasma or urine quantitatively reflect oxidative damage to the central nervous system. Our results showed that urine levels of F 2‐IsoPs or their major metabolite were not significantly different between 56 Alzheimer's disease patients and 34 controls. In addition, urine and cerebrospinal fluid F 2‐IsoP levels in 32 Alzheimer's disease patients did not correlate. Supporting these conclusions, elevated rat cerebral F 2‐IsoPs and F 4‐NeuroPs after systemic exposure to kainic acid were not associated with a significant change in their plasma or urine levels. These results show that plasma and urine F 2‐IsoPs and F 4‐NeuroPs do not accurately reflect central nervous system levels of these biomarkers and are not reproducibly elevated in body fluids outside of central nervous system in Alzheimer's disease patients. These results should guide the organization of clinical trials now being planned for patients with Alzheimer's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Increased F 2 ‐isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo
Pratico, D., Lee, V. M.-Y., Trojanowski, J. Q., Rokach, J., & Fitzgerald, G. A. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.15.1777 · Cited by 405 · cited 1×
“These studies have used several biomarkers including F2-isoprostanes (F2-IsoPs), quantitative in vivo biomarkers of free radical damage to arachidonic acid.(5,6) Moreover, F2-IsoP levels are increased in cerebrospinal fluid (CSF) obtained postmortem from the lateral ventricle of definite AD patients with advanced deme…”
Method
Cited by
Halliwell, B., & Whiteman, M. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705776 · Cited by 2,238
Biomarkers of Oxidative Damage in Human Disease
Dalle-Donne, I., Rossi, R., Colombo, R., Giustarini, D., & Milzani, A. (2006) · Clinical Chemistry · doi:10.1373/clinchem.2005.061408 · Cited by 1,703
The role of reactive oxygen and antioxidant species in periodontal tissue destruction
Chapple, I. L. C., & Matthews, J. B. (2007) · Periodontology 2000 · doi:10.1111/j.1600-0757.2006.00178.x · Cited by 936
Oxidative stress in brain aging, neurodegenerative and vascular diseases: An overview
Mariani, E., Polidori, M. C., Cherubini, A., & Mecocci, P. (2005) · Journal of Chromatography B · doi:10.1016/j.jchromb.2005.04.023 · Cited by 680
Evidence of increased oxidative damage in subjects with mild cognitive impairment
Keller, J. N., Schmitt, F. A., Scheff, S. W., Ding, Q., Chen, Q., Butterfield, D. A., & Markesbery, W. R. (2005) · Neurology · doi:10.1212/01.wnl.0000156156.13641.ba · Cited by 539
Lipids and Alzheimer’s Disease
Kao, Y.-C., Ho, P.-C., Tu, Y.-K., Jou, I.-M., & Tsai, K.-J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041505 · Cited by 485
Morrow, J. D. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000152605.64964.c0 · Cited by 453
Self-citationLooking Backward to Move Forward: Early Detection of Neurodegenerative Disorders
DeKosky, S. T., & Marek, K. (2003) · Science · doi:10.1126/science.1090349 · Cited by 406
The isoprostanes—25 years later
Milne, G. L., Dai, Q., & Roberts, L. J. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.10.007 · Cited by 335
“Importantly, measurement of F2IsoPs in the plasma or urine does not consistently show increases in these diseases while their measurement in cerebral spinal fluid (CSF) is more indicative of the changes in oxidative stress in the brain [146,147].”
BackgroundSelf-citationOxidative Stress in Alzheimer’s Disease: Why Did Antioxidant Therapy Fail?
Persson, T., Popescu, B. O., & Cedazo-Minguez, A. (2014) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2014/427318 · Cited by 312
Anticholinesterase Toxicity and Oxidative Stress
Milatovic, D., Gupta, R. C., & Aschner, M. (2006) · The Scientific World JOURNAL · doi:10.1100/tsw.2006.38 · Cited by 284
Self-citationLipid peroxidation is an early event in the brain in amnestic mild cognitive impairment
Markesbery, W. R., Kryscio, R. J., Lovell, M. A., & Morrow, J. D. (2005) · Annals of Neurology · doi:10.1002/ana.20629 · Cited by 273
Self-citationF 2 -Isoprostanes in Human Health and Diseases: From Molecular Mechanisms to Clinical Implications
Basu, S. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1956 · Cited by 268
Biomarkers of Alzheimer disease in plasma
Irizarry, M. C. (2004) · NeuroRX · doi:10.1602/neurorx.1.2.226 · Cited by 268
Oxidative damage in Parkinson disease: Measurement using accurate biomarkers
Seet, R. C. S., Lee, C.-Y. J., Lim, E. C. H., Tan, J. J. H., Quek, A. M. L., Chong, W.-L., Looi, W.-F., Huang, S.-H., Wang, H., Chan, Y.-H., et al. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.11.026 · Cited by 257
Prevention of Alzheimer's disease: Omega-3 fatty acid and phenolic anti-oxidant interventions
Cole, G. M., Lim, G. P., Yang, F., Teter, B., Begum, A., Ma, Q., Harris-White, M. E., & Frautschy, S. A. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.09.005 · Cited by 225
Biochemical markers in persons with preclinical familial Alzheimer disease
Ringman, J. M., Younkin, S. G., Pratico, D., Seltzer, W., Cole, G. M., Geschwind, D. H., Rodriguez-Agudelo, Y., Schaffer, B., Fein, J., Sokolow, S., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000303973.71803.81 · Cited by 198
Sultana, R., Mecocci, P., Mangialasche, F., Cecchetti, R., Baglioni, M., & Butterfield, D. A. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-101425 · Cited by 111
DYKENS, J. A., MOOS, W. H., & HOWELL, N. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1347.008 · Cited by 87
Oxidative challenge in Alzheimer's disease: state of knowledge and future needs
Cervellati, C., Wood, P. L., Romani, A., Valacchi, G., Squerzanti, M., Sanz, J. M., Ortolani, B., & Zuliani, G. (2016) · Journal of Investigative Medicine · doi:10.1136/jim-2015-000017 · Cited by 75
Phytochemicals in Alzheimer disease, the development of clinical trials
Quinn, J., Kaye, J., Montine, T., & Stackman, R. (2004) · Pharmaceutical Biology · doi:10.3109/138802090893531 · Cited by 8
“Due to uncertainty regarding active ingredients, the clinical trials described with Ginkgo biloba are being conducted without a rigorous demonstration of bioavailability or CNS penetration of the agent, a reasonable approach given the abundant animal data showing CNS effects of orally administered Ginkgo biloba (Winte…”
BackgroundSelf-citation
Metadata
- Authors
- Montine, T. J., Quinn, J. F., Milatovic, D., Silbert, L. C., Dang, T., Sanchez, S., Terry, E., Roberts, L. J., Kaye, J. A., & Morrow, J. D.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2002-07-23
- Volume
- 52
- Issue
- 2
- Pages
- 175-179
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2055021833
- Cited by
- 155
- References
- 1
- FWCI
- 5.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.